Melanoma Dispatch
Follow
Find tag "PD-1 inhibitor"
1.9K views | +4 today
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

ASCO: Targeting PD-1 Works in Advanced Melanoma

ASCO: Targeting PD-1 Works in Advanced Melanoma | Melanoma Dispatch | Scoop.it

"Two studies indicate that using investigative immunotherapy drugs improves survival and response in patients with metastatic melanoma, researchers said here.


"In one study, the agent pembrolizumab (MK-3475) which targets the programmed death (PD-1) pathway produced a 1-year 69% survival rate, said Antoni Ribas, MD, PhD, professor of medicine at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles.


"In a second study reported in a press conference at the annual meeting of the American Society of Clinical Oncology, Mario Sznol, MD, professor of medicine at the Yale Cancer Center, demonstrated that a combination of the investigative PD-1 inhibitor nivolumab in combination with another targeted agent ipilimumab (Yervoy) produced a 1-year survival rate of 85% and 2-year survival rate of 79% for advanced melanoma patients."


Editor's note: Immunotherapy drugs boost a patient's own immune system to fight cancer. Promising research into new immunotherapy drugs for melanoma was recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Two treatments that received special attention were MK-3475 (aka pembrolizumab) and a combination of the drugs ipilimumab (Yervoy) and nivolumab.

Cancer Commons's insight:

MedPage Today  |  Jun 5, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Killing Cancer through the Immune System

Killing Cancer through the Immune System | Melanoma Dispatch | Scoop.it

"The immune system has this blind spot by design – an immune system that has an ability to attack itself leads to autoimmune diseases, so as protection, it screens out its own tissue.


"For decades, scientists assumed that cancer was beyond the reach of the body's natural defenses. But after decades of skepticism that the immune system could be trained to root out and eliminate these malignant cells, a new generation of drugs is proving otherwise.


"The treatment consists of infusing antibodies that enhance the immune system to recognize cancer cells and attack it. What's more, since the immune system has a built-in memory, it continues to go after cancer cells, so the response can be longer lasting and more complete.


"The trick is that this treatment doesn't work for everybody, and researchers don't yet understand why. But when it does work, the results have been particularly impressive."

Cancer Commons's insight:

Medical Xpress  |  Feb 4, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

At Last, Success Seen in Fighting Cancer with the Immune System

At Last, Success Seen in Fighting Cancer with the Immune System | Melanoma Dispatch | Scoop.it

"Fundamental research -- much of it done in Boston -- has led to a shift in the scientific strategy for fighting some cancers, toward using drugs to activate a patient’s own immune system. An approach that was on the fringes of cancer therapy is suddenly the hottest trend in cancer drug development. On Monday, for example, Boston researchers presented data showing that nearly half of patients with advanced melanoma lived for two years after getting an experimental immune therapy called nivolumab, though multiple other therapies hadn’t worked for them. And drug companies have announced several deals recently to acquire companies developing immunotherapies. The frenzy of activity is an abrupt change for a field that had made big promises but failed to deliver for years."

Cancer Commons's insight:

The Boston Globe  |  Mar 10, 2014

more...
No comment yet.